Crystal clear activity could possibly be demonstrated with the potential to further maximize the result by optimizing the dosage regimen and extending the procedure duration,’ stated Jens-Peter Marschner, MD, Chief Medical Officer of Affimed. ‘These data are promising, in particular since there is no alternate treatment option for sufferers in this setting. A phase 2 study investigating an optimized dosage regimen will end up being initiated this year.’.. Affimed Therapeutics reports extra results from AFM13 phase 1 study about R/R Hodgkin lymphoma Affimed Therapeutics AG announced today further results from its phase 1 clinical trial of AFM13 as monotherapy for the treating patients with advanced relapsing/refractory Hodgkin lymphoma. In the clinical phase 1 study, 28 heavily pretreated patients experiencing R/R Hodgkin lymphoma received infusions of AFM13 with increasing dosages in the number of 0.01 mg/kg up to 7 mg/kg.‘This collaborative is definitely a significant milestone to improve look after surgical patients inside our condition because it we can generate a positive learning environment among all participating hospitals and work together to determine where improvement is necessary most,’ stated John Sweeney, MD, FACS, W. Dean Warren Distinguished Professor of Surgery treatment, and chief, Division of Gastrointestinal and General Surgery, Department of Surgery, Emory University College of Medicine. ‘Since it stands, hospitals can't fix errors if they don't understand a nagging issue exists. Examining and comparing scientific outcomes data with this peers from each corner of the state will help us move the needle to boost patient outcomes and reduce overall health care costs.’ A recent study by Sweeney, et al.1 %).